top of page

PSARLink by Mablink Bioscience

Our unique technology enables the design of ADCs with improved efficacy and better tolerability while unlocking the use of novel payloads

Next-generation antibody-drug conjugates
powered by the exclusive ​PSARLink™ platform 

MBK-103
our lead ADC candidate

  • Validated druggable target: FR⍺
  • Potential to address:
    • Ovarian Cancer,
    • Triple Negative Breast Cancer,
    • Non-Small Cell Lung Cancer,
    • Colorectal Cancer
  • Exatecan (anti topo-I) as payload
     
  • Excellent pharmacological profile thanks to PSARLink™ 
 
Clinical trials planned to start in 2024 based on promising preclinical results.
MBK-103

News

Upcoming events

  • BIO International Convention
    Jun 05, 9:00 AM CST – Jun 08, 9:00 AM CST
    Boston, 415 Summer Street, Boston, MA 02210, États-Unis
    Share
  • Antibody engineering & therapeutics Europe
    Jun 06, 9:00 AM – Jun 08, 9:00 AM
    Amsterdam, Paul van Vlissingenstraat 9, 1096 BK Amsterdam, Pays-Bas
    Share
  • VivaTech
    Wed, Jun 14
    Paris Expo Porte de Versailles
    Jun 14, 9:00 AM GMT+2 – Jun 17, 6:00 PM GMT+2
    Paris Expo Porte de Versailles , 1 Place de la Porte de Versailles F-75015 Paris France
    Share
  • ADC Toxicity Summit
    Tue, Jul 25
    Boston
    Jul 25, 9:00 AM CST – Jul 27, 9:00 AM CST
    Boston, 1 Ave de Lafayette, Boston, MA 02111, USA
    Delivering More Tolerable ADCs to Patients
    Share
  • World ADC
    Mon, Oct 16
    San Diego
    Oct 16, 9:00 AM PDT – Oct 19, 4:50 PM PDT
    San Diego, 1380 Harbor Island Dr, San Diego, CA 92101, USA
    Accelerate Your Antibody-Drug Conjugate Pipeline to Become a Front-Line Treatment
    Share
  • BIO-Europe
    Mon, Nov 06
    München
    Nov 06, 9:00 AM CST – Nov 08, 9:00 AM CST
    München, Am Messeturm, 81829 München, Allemagne
    Share
bottom of page